Holen Sie sich die Stockscreener-App
13.69
3.56%
0.47
Handel nachbörslich:
13.69
Schlusskurs vom Vortag:
$13.22
Offen:
$13.29
24-Stunden-Volumen:
163.00K
Relative Volume:
0.89
Marktkapitalisierung:
$298.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-12.30%
1M Leistung:
+39.13%
6M Leistung:
+13.33%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.90
$13.97
1-Wochen-Bereich:
$12.90
$15.97
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie AARD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.69 | 287.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-07 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
How resilient is Aardvark Therapeutics Inc. stock in market downturns2025 Market Sentiment & Technical Pattern Based Signals - Улправда
Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat
Insider Stock Purchases: December 13, 2025 - Quiver Quantitative
William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria
Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus
Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Sahm
William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy By Investing.com - Investing.com South Africa
Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com Canada
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Nigeria
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target By Investing.com - Investing.com South Africa
Aardvark doses first Australian patient in phase 3 PWS hunger trial - Investing.com Nigeria
Aardvark doses first Australian patient in phase 3 PWS hunger trial By Investing.com - Investing.com South Africa
Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing - TipRanks
Aardvark Therapeutics Doses First Patient in HERO Phase 3 Trial - TradingView — Track All Markets
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome - The Manila Times
Aardvark Therapeutics (Nasdaq: AARD) expands HERO PWS trial, targets Q3 2026 data - Stock Titan
Retail Investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 28% Last Week - 富途牛牛
Will Aardvark Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Daily Market Momentum Tracking - Newser
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Raymond James Financial Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st
Aardvark Therapeutics initiated with a Strong Buy at Raymond James - MSN
AARD: Phase 3 Prader-Willi data expected Q3 2026; obesity program readout by end of next year - TradingView
Aardvark Therapeutics (AARD) Stock Analysis Report | Financials & Insights - Benzinga
Raymond James Initiates Aardvark Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com UK
AARDAardvark Therapeutics Inc Dividends - Finviz
Aardvark Therapeutics Reports Q3 2025 Financial Results - MSN
Aardvark Therapeutics Hosts Investor Webinar on Drug Programs - MSN
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):